Innate Pharma (OTCMKTS:IPHYF – Get Rating) and Aligos Therapeutics (NASDAQ:ALGS – Get Rating) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk. Analyst Ratings This is a breakdown of current recommendations and […]
Innate Pharma (NASDAQ:IPHA – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday, Zacks.com reports. According to Zacks, “Innate Pharma S.A. is a commercial stage oncology-focused biotech company. It discovers and develops therapeutic antibodies for the treatment of cancer. The […]
Innate Pharma (OTCMKTS:IPHYF – Get Rating) and Immunovant (NASDAQ:IMVT – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability. Risk & Volatility Innate Pharma has a beta of 0.67, […]
Innate Pharma S.A. (NASDAQ:IPHA – Get Rating) – Stock analysts at SVB Leerink dropped their FY2026 earnings estimates for shares of Innate Pharma in a research report issued on Tuesday, May 10th. SVB Leerink analyst D. Graybosch now anticipates that the company will earn $0.58 per share for the year, down from their previous forecast […]
Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.